Markets News
Forex and Market News
Forex GOLD Investor
Forex GOLD Investor
Bitcoin (BTC)
$10,913.86
+1.21%
Ethereum (ETH)
$358.96
-0.29%
Litecoin (LTC)
$46.49
+0.19%
DigitalCash (DASH)
$69.42
-0.12%
Monero (XMR)
$98.07
+2.92%
Nxt (NXT)
$0.01
0%
Ethereum Classic (ETC)
$5.76
-0.72%
Dogecoin (DOGE)
$0.00
-3.85%
ZCash (ZEC)
$56.21
-0.97%
Bitshares (BTS)
$0.02
-1.73%
DigiByte (DGB)
$0.02
-0.45%
Ripple (XRP)
$0.24
+0.53%
BitcoinDark (BTCD)
$27.42
0%
PeerCoin (PPC)
$0.22
+1.41%
CraigsCoin (CRAIG)
$0.00
0%
Bitstake (XBS)
$1.10
0%
PayCoin (XPY)
$0.05
0%
ProsperCoin (PRC)
$0.01
0%
YbCoin (YBC)
$1,342.65
0%
DarkKush (DANK)
$0.00
0%

Celyad Oncology Establishes At-the-Market Facility

Forex GOLD Investor


Regulatory News:

Celyad Oncology currently intends to use net proceeds from sales of ADSs in the ATM for general corporate purposes, including but not limited to the research and development of Company’s clinical and preclinical CAR T cell therapy candidates.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-547-6340 or by email at Prospectus_Department@Jefferies.com.” data-reactid=”27″The securities are being offered pursuant to a shelf registration statement on Form F-3 (333-248464), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 4, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A prospectus supplement relating to the offering was filed by Celyad Oncology with the SEC on September 11, 2020 and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-547-6340 or by email at Prospectus_Department@Jefferies.com.

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

This release…



Read More: Celyad Oncology Establishes At-the-Market Facility

Forex GOLD Investor
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.